Ensysce Biosciences has reported the latest data on its delivery technology for short interfering RNA (siRNA) for therapeutic applications in the Materials journal.
In the article titled ‘Carbon Nanotubes: Solution for the Therapeutic Delivery of siRNA,’ Ensysce Biosciences has emphasized the utilization of carbon nanotubes in therapeutic applications and has reported its latest developments, as it shifts its platform toward a Phase 1 clinical study and IND enabling studies.
The State of Texas Emerging Technology Fund has awarded a $1.5 million grant to Ensysce Biosciences to develop single walled carbon nanotube therapeuctics, which include the delivery platform of siRNA. The latest data demonstrates the advancement of this potential technology.
According to the data, single walled carbon nanotubes not only safeguard the siRNA payload during its circulation in the bloodstream but also introduce the siRNA in to tumors and generate knockdown of the targeted proteins with anti-cancer activity. Ensysce Biosciences’ aim is to improve its single walled carbon nanotube formulation and shift its siRNA/single walled carbon nanotube product into clinical development. Carbon nanotubes act as a carrier to supply large active agents via natural barriers inside the body, especially into cancer cells.
The Chief Executive Officer at Ensysce Biosciences, Dr. Lynn Kirkpatrick stated that the company is improving the pharmaceutical preparations to show the common behavior of the single walled carbon nanotube carriers for siRNA delivery and expect to start clinical trials within the coming 12 to 18 months.
The company is located in the Biotechnology Commercialization Center in the Texas Medical Center, which has allowed the company to establish research partnerships with Rice University and M.D. Anderson Cancer Center.
Source: http://www.ensysce.com